NCT04602845 is a Phase 4 clinical trial of Fentanyl in Sedation Complication, sponsored by Peking University.

Who is sponsoring NCT04602845?

NCT04602845 is sponsored by Peking University.

What drugs are being tested in NCT04602845?

Interventions in NCT04602845: Fentanyl, Flurbiprofen, Midazolam, Remimazolam.

What condition does NCT04602845 study?

NCT04602845 studies Sedation Complication, Midazolam, Remimazolam.

Is NCT04602845 still recruiting?

NCT04602845 is currently completed. Last updated 15 March 2022.

Last reviewed 2022-03-15 · How we verify

NCT04602845

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients

Completed Phase 4 Last updated 15 March 2022

What this trial tests

Phase 4 trial testing Fentanyl in Sedation Complication in 81 participants. Completed in 31 December 2021.

Timeline

1 April 2021

Primary endpoint
30 June 2021

31 December 2021

Quick facts

Lead sponsor	Peking University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	81
Start date	1 April 2021
Primary completion	30 June 2021
Estimated completion	31 December 2021
Sites	2 locations across China

Drugs / interventions tested

Fentanyl (fentanyl) — full drug profile →
Flurbiprofen (flurbiprofen) — full drug profile →
Midazolam (midazolam) — full drug profile →
Remimazolam — full drug profile →

Conditions studied

Sedation Complication — all drugs for Sedation Complication →
Midazolam — all drugs for Midazolam →
Remimazolam — all drugs for Remimazolam →

Sponsor

Peking University

Who can join

Adults 18 to 60, any sex, with Sedation Complication or Midazolam. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Remimazolam Tosilate is a new short-acting benzodiazepines used in sedation. It has the advantages of rapid metabolism, quick recovery without injection pain. This study aims to compared with Midazolam, study whether Remimazolam Tosilate can achieve the same sedation effect with lower side effects on sedation maintenance period, During the recovery period of anesthesia, can Remimazolam Tosilatebe more stable and rapid.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Fentanyl

Trials testing the same drug.

NCT07435337 — Effect of Nalbuphine Versus Fentanyl on Hemdoynamic Effects of Laryngoscopy · Phase 4 · recruiting
NCT07276867 — Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia f · NA · recruiting
NCT06763705 — Comparison of Safety and Efficacy for Different Sedation Regimens During Colonoscopy · Phase 4 · recruiting
NCT06772727 — Lidocaine-based Versus Opioid-based Induction of Anesthesia in Emergency Laparotomy · Phase 4 · completed
NCT06561672 — Paracetamol Plus Tramadol Versus Fentanyl As Preemptive Analgesia For Enhanced Recovery After Day Case Surgeries · EARLY_PHASE1 · enrolling by invitation

Other recruiting trials for Sedation Complication

Currently open trials in the same condition.

NCT06667869 — multipaRameter mOnitoring systeM for sedAtion iNThe ICu · recruiting
NCT07456111 — A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy · Phase 4 · recruiting
NCT06769308 — Effect of Goal-directed Analgesia and Sedation Using EEG Derived QCON/qNOX in ICU Patients · NA · recruiting
NCT05371886 — Pharmacokinetics-pharmacodynamics of Morphine With or Without Midazolam Administered by Continuous Infusion in Neonatal · NA · recruiting
NCT05765162 — Safe Brain Initiative, Operationalizing Precision Anaesthesia · recruiting

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04602845 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 15 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04602845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing